Novel metabolic markers for the risk of diabetes development in American Indians

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 220-227

  Zhao, Jinying ^a   Zhu, Yun ^a   Hyun, Noorie ^b   Zeng, Donglin ^b   Uppal, Karan ^c   Tran, Vilinh T ^c   Yu, Tianwei ^d   Jones, Dean ^c   He, Jiang ^a   Lee, Elisa T ^e   Howard, Barbara V ^f  

^a TULANE UNIVERSITY   (United States)

^b IL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f Center for Science Economics and the Environment   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBIPHENYL; 7 HYDROXY 29,39,49,59,8 PENTAMETHOXYISOFLAVAN; BIOLOGICAL MARKER; FLAVONOID; GLUCOSE; GLYCEROPHOSPHORYLCHOLINE; LEUCYLASPARTYLTYROSYLARGININE; LIPID; LIPOPROTEIN; METHIONYLGLUTAMYLISOLEUCYLARGININE; PHOSPHATIDYLCHOLINE; TETRAPEPTIDE; UNCLASSIFIED DRUG; X 490; 2-PHENYLPHENOL; 7-HYDROXY-2',3',4',5',8-PENTAMETHOXYISOFLAVAN; BIPHENYL DERIVATIVE; ISOFLAVONE DERIVATIVE; OLIGOPEPTIDE;

ADULT; AMERICAN INDIAN; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; ETHNOLOGY; METABOLISM; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADULT; BIOMARKERS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; INSULIN RESISTANCE; ISOFLAVONES; LOGISTIC MODELS; MALE; METABOLOMICS; OLIGOPEPTIDES; PHOSPHATIDYLCHOLINES; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84921925385     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2033     Document Type: Article

References (47)

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
2. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
3. Würtz P, Mäkinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7, 098 young adults. Diabetes 2012;61:1372-1380
4. Wopereis S, Rubingh CM, Van Erk MJ, et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 2009;4:e4525
5. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e13953
6. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete longchain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009;139:1073-1081
7. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010;5:e15234
8. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012;8:615
9. Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013;62:4270-4276
10. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
11. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639-648
12. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013;62:1730-1737
13. North KE, Howard BV, Welty TK, et al. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol 2003;157:303-314
14. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-1155
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl. 1):S5-S20
16. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-246 [in German]
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
19. Willett W. Food frequency methods. In Nutritional Epidemiology. 2nd ed. New York, Oxford University Press, 1998, p. 74-91
20. Osborn MP, Park Y, Parks MB, et al. Metabolome-wide association study of neovascular age-related macular degeneration. PLoS ONE 2013;8:e72737
21. Roede JR, Uppal K, Park Y, et al. Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS ONE 2013;8:e77629
22. Yu T, Park Y, Johnson JM, Jones DP. apLCMSdadaptive processing of high-resolution LC/MS data. Bioinformatics 2009;25:1930-1936
23. Yu T, Park Y, Li S, Jones DP. Hybrid feature detection and information accumulation using high-resolution LC-MS metabolomics data. J Proteome Res 2013;12:1419-1427
24. Uppal K, Soltow QA, Strobel FH, et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinformatics 2013;14:15
25. Smith CA, O'Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit 2005;27:747-751
26. Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res 2013;41:D801-D807
27. Sud M, Fahy E, Cotter D, et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res 2007;35:D527-D532
28. Hughes G, Cruickshank-Quinn C, Reisdorph R, et al. MSPrep-summarization, normalization and diagnostics for processing of mass spectrometrybased metabolomic data. Bioinformatics 2014;30:133-134
29. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-127
30. Storey JD. A direct approach to false discovery rates. J R Stat Soc Series B Stat Methodol 2002;64:187-205
31. Suzuki H, Suzuki N, Sasaki M, Hiraga K. Orthophenylphenol mutagenicity in a human cell strain. Mutat Res 1985;156:123-127
32. Brusick D. Analysis of genotoxicity and the carcinogenic mode of action for ortho-phenylphenol. Environ Mol Mutagen 2005;45:460-481
33. Hagiwara A, Shibata M, Hirose M, Fukushima S, Ito N. Long-term toxicity and carcinogenicity study of sodium o-phenylphenate in B6C3F1 mice. Food Chem Toxicol 1984;22:809-814
34. Sondossi M, Sylvestre M, Ahmad D, Masse R. Metabolism of hydroxybiphenyl and cholorohydroxybiphenyl by biphenyl/cholorobiphenyl degradign Pseudomonas testosteroni, strain B-356. J Ind Microbiol 1991;6:77-88
35. Gall WE, Beebe K, Lawton KA, et al.; RISC Study Group. alpha-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 2010;5:e10883
36. Van Dam RM, Naidoo N, Landberg R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr Opin Lipidol 2013;24:25-33
37. Wedick NM, Pan A, Cassidy A, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 2012;95:925-933
38. Zamora-Ros R, Forouhi NG, Sharp SJ, et al. The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. Diabetes Care 2013;36:3961-3970
39. Chen YK, Cheung C, Reuhl KR, et al. Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. J Agric Food Chem 2011;59:11862-11871
40. Lotito SB, Zhang WJ, Yang CS, Crozier A, Frei B. Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. Free Radic Biol Med 2011;51:454-463
41. Friedrich M, Petzke KJ, Raederstorff D, Wolfram S, Klaus S. Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int J Obes (Lond) 2012;36:735-743
42. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011;89:667-676
43. Leiherer A, Mündlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 2013;58:3-20
44. Ortsäter H, Grankvist N, Wolfram S, Kuehn N, Sjöholm A. Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr Metab (Lond) 2012;9:11
45. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007;24:223-232
46. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678-1683
47. Stancáková A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9, 369 Finnish men. Diabetes 2012;61:1895-1902